Authors
Ethan Basch, Bryce B Reeve, Sandra A Mitchell, Steven B Clauser, Lori M Minasian, Amylou C Dueck, Tito R Mendoza, Jennifer Hay, Thomas M Atkinson, Amy P Abernethy, Deborah W Bruner, Charles S Cleeland, Jeff A Sloan, Ram Chilukuri, Paul Baumgartner, Andrea Denicoff, Diane St. Germain, Ann M O’Mara, Alice Chen, Joseph Kelaghan, Antonia V Bennett, Laura Sit, Lauren Rogak, Allison Barz, Diane B Paul, Deborah Schrag
Publication date
2014/9/1
Journal
Journal of the National Cancer Institute
Volume
106
Issue
9
Pages
dju244
Publisher
Oxford University Press
Description
The standard approach for documenting symptomatic adverse events (AEs) in cancer clinical trials involves investigator reporting using the National Cancer Institute’s (NCI’s) Common Terminology Criteria for Adverse Events (CTCAE). Because this approach underdetects symptomatic AEs, the NCI issued two contracts to create a patient-reported outcome (PRO) measurement system as a companion to the CTCAE, called the PRO-CTCAE. This Commentary describes development of the PRO-CTCAE by a group of multidisciplinary investigators and patient representatives and provides an overview of qualitative and quantitative studies of its measurement properties. A systematic evaluation of all 790 AEs listed in the CTCAE identified 78 appropriate for patient self-reporting. For each of these, a PRO-CTCAE plain language term in English and one to three items characterizing the frequency, severity, and/or …
Total citations
201520162017201820192020202120222023202421656689749713211414583